U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H9NO6
Molecular Weight 191.1388
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISOSORBIDE MONONITRATE

SMILES

O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O

InChI

InChIKey=YWXYYJSYQOXTPL-SLPGGIOYSA-N
InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19538173https://www.drugs.com/pro/sodium-nitroprusside.html | https://www.ncbi.nlm.nih.gov/pubmed/7598246https://www.ncbi.nlm.nih.gov/pubmed/8644642 | https://www.ncbi.nlm.nih.gov/pubmed/7504768 | https://www.ncbi.nlm.nih.gov/pubmed/1724528 | https://adisinsight.springer.com/drugs/800001151https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19601018&CC=US&NR=2957021A&KC=A | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20020124&CC=WO&NR=0205795A2&KC=A2http://www.ncbi.nlm.nih.gov/pubmed/6985697https://www.ncbi.nlm.nih.gov/pubmed/13426891 | https://www.ncbi.nlm.nih.gov/pubmed/13284675http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/19732062 | https://www.ncbi.nlm.nih.gov/pubmed/28988245 | https://www.ncbi.nlm.nih.gov/pubmed/24923291 | https://www.ncbi.nlm.nih.gov/pubmed/19563531https://adisinsight.springer.com/drugs/800005482 | https://www.ncbi.nlm.nih.gov/pubmed/9845803http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020845s016s017lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019790s011lbl.pdfwww.ncbi.nlm.nih.gov/pubmed/24071762
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/13106442

Pentaerythritol tetranitrate is an organic nitrate that has been used for the treatment of angina pectoris. Upon administration, the drug undergoes exstensive metabolism to NO which causes vasodilation and the relaxation of smooth muscle cells. The compound belongs to a familiy of explosive substances and may be used accordingly.

CNS Activity

Curator's Comment: NO can be generated in large quantities and has detrimental effects on the CNS. NO has been shown to increase permeability of the BBB, allowing substances to enter into the brain passively.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
NIPRIDE

Approved Use

Sodium Nitroprusside injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with Sodium Nitroprusside can be minimized. Sodium Nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium Nitroprusside injection is also indicated for the treatment of acute congestive heart failure.

Launch Date

1974
Primary
NIPRIDE

Approved Use

Sodium Nitroprusside injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with Sodium Nitroprusside can be minimized. Sodium Nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium Nitroprusside injection is also indicated for the treatment of acute congestive heart failure.

Launch Date

1974
Palliative
INOMAX

Approved Use

INOmax is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

Launch Date

1999
Primary
DILATRATE-SR

Approved Use

dilatrate®-SR sustained release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.

Launch Date

1998
Primary
MONOKET

Approved Use

monoket® is indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.

Launch Date

1993
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
NITROSTAT

Approved Use

Acute relief of angina pectoris secondary to CAD; acute prophylactic management in situations likely to provoke angina attacks; and long-term prophylactic management of angina pectoris.

Launch Date

2000
Primary
NITROGLYCERIN

Approved Use

Management of patients with acute myocardial infarction (MI). Nitroglycerin is one of the principal initial therapies of MI.

Launch Date

1981
Primary
NITROGLYCERIN

Approved Use

IV nitroglycerin is used to control BP in perioperative hypertension, especially hypertension associated with cardiovascular procedures; to control BP in patients with severe hypertension† or in hypertensive crises for the immediate reduction of BP in patients in whom such reduction is considered an emergency (hypertensive emergencies), especially those associated with coronary complications (e.g., coronary ischemia, acute coronary insufficiency, acute left ventricular failure, postoperative hypertension [especially following coronary bypass surgery]); and to produce controlled hypotension during surgical procedures.

Launch Date

1981
Primary
NITROGLYCERIN

Approved Use

IV nitroglycerin has been used in the management of acutely decompensated (e.g., congestive) heart failure and other low cardiac-output states.

Launch Date

1981
Primary
Metamine

Approved Use

https://www.ncbi.nlm.nih.gov/pubmed/13426891 | https://www.ncbi.nlm.nih.gov/pubmed/13284675
Primary
PERITRATE

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
187 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOSORBIDE DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
356 ng/mL
20 mg single, intravenous
dose: 20 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
388 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
557 ng/mL
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1151 ng/mL
120 mg 1 times / day steady-state, oral
dose: 120 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
84 ng/mL
13 mg single, oral
dose: 13 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLYCERYL 1,2-DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.7 pg/mL
800 μg single, sublingual
dose: 800 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
NITROGLYCERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
17 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTAERYTHRITOL DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.5 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTAERYTHRITOL DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
79 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTAERYTHRITOL MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
35 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTAERYTHRITOL MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
15 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
29.7 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
17.9 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.4 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.3 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.89 ng/mL/kg
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.03 ng/mL/kg
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.26 ng/mL/kg
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.08 ng/mL/kg
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
32 μg/L
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
37 μg/L
16 mg 1 times / day multiple, oral
dose: 16 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8 μg/L
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8 μg/L
16 mg 1 times / day multiple, oral
dose: 16 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
32 μg/L
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
34 μg/L
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
8 μg/L
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10 μg/L
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1458 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOSORBIDE DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2647 ng × h/mL
20 mg single, intravenous
dose: 20 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2524 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6979 ng × h/mL
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14241 ng × h/mL
120 mg 1 times / day steady-state, oral
dose: 120 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3380 ng × min/mL
13 mg single, oral
dose: 13 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLYCERYL 1,2-DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
12.3 pg × min/mL
800 μg single, sublingual
dose: 800 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
NITROGLYCERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
106.5 μg × h/L
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
31.7 μg × h/L
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12.2 μg × h/L
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.4 μg × h/L
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
17.54 ng × h/mL/kg
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.5 ng × h/mL/kg
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.46 ng × h/mL/kg
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.11 ng × h/mL/kg
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
311 ng × h/mL
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
423 ng × h/mL
16 mg 1 times / day multiple, oral
dose: 16 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
60 ng × h/mL
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
61 ng × h/mL
16 mg 1 times / day multiple, oral
dose: 16 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
335 ng × h/mL
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
310 ng × h/mL
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
49 ng × h/mL
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
70 ng × h/mL
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
303 min
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOSORBIDE DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 h
20 mg single, intravenous
dose: 20 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.2 h
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.2 h
120 mg 1 times / day steady-state, oral
dose: 120 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
50 min
13 mg single, oral
dose: 13 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLYCERYL 1,2-DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
40 min
800 μg single, sublingual
dose: 800 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
NITROGLYCERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2 min
single, intravenous
NITROPRUSSIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.5 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTAERYTHRITOL DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.5 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTAERYTHRITOL DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
10.5 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTAERYTHRITOL MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
10.5 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTAERYTHRITOL MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.6 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.9 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.2 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.8 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
13.1 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.5 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.2 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
12 h
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12 h
16 mg 1 times / day multiple, oral
dose: 16 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10 h
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12 h
16 mg 1 times / day multiple, oral
dose: 16 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
9.7 h
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8.2 h
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
6.6 h
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.8 h
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LINSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
ISOSORBIDE DINITRATE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
100%
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOLSIDOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Other AEs: Headache, Dizziness...
Other AEs:
Headache (50%)
Dizziness (32%)
Asthenia (14%)
Nausea (10%)
Bronchitis (8%)
Hypotension (8%)
Sinusitis (4%)
Ventricular tachycardia (4%)
Hyperglycemia (4%)
Rhinitis (4%)
Paresthesia (4%)
Vomiting (4%)
Amblyopia (3%)
Hyperlipidemia (3%)
Tachycardia (2%)
Sources:
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Disc. AE: Chest pain, Heart arrest...
AEs leading to
discontinuation/dose reduction:
Chest pain (0.6%)
Heart arrest (0.6%)
Heart failure (0.6%)
Hypotension (0.6%)
Kidney failure (0.6%)
Infection (0.4%)
Ventricular fibrillation (0.4%)
Dizziness (0.4%)
Arrhythmia (0.2%)
Cerebrovascular accident (0.2%)
Syncope (0.2%)
Gastroenteritis (0.2%)
Myasthenia (0.2%)
Dyspnea (0.2%)
Edema lung (0.2%)
Angioedema (0.2%)
Breast carcinoma (0.2%)
Uremia (0.2%)
Sources:
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Other AEs: Chest pain, Heart failure...
Other AEs:
Chest pain (6.4%)
Heart failure (3.1%)
Ventricular tachycardia (2.7%)
Pneumonia (2.3%)
Syncope (2.1%)
Dyspnea (1.9%)
Arrhythmia (1.7%)
Hypotension (1.5%)
Heart arrest (1.4%)
Cerebrovascular accident (1.4%)
Dizziness (1.4%)
Cellulite (1.2%)
Cerebral ischemia (1%)
Coronary artery disease (1%)
Anemia (1%)
Bronchitis (1%)
Dehydration (1%)
Angina pectoris (1%)
Hyperglycemia (1%)
Hypoglycemia (1%)
Infection (1%)
Acute kidney failure (1%)
Neoplasm (0.8%)
Gout (0.8%)
Atrial fibrillation (0.8%)
Gastrointestinal hemorrhage (0.8%)
Kidney failure (0.8%)
Myocardial infarct (0.8%)
Sepsis (0.6%)
Asthma (0.6%)
Accidental injury (0.6%)
Cholecystitis (0.6%)
Cholelithiasis (0.6%)
Supraventricular tachycardia (0.6%)
Esophagitis (0.4%)
Edema lung (0.4%)
Headache (0.4%)
Osteomyelitis (0.4%)
Peripheral vascular disease (0.4%)
Bradycardia (0.4%)
Digitalis intoxication (0.4%)
Gastroenteritis (0.4%)
Hyperkalemia (0.4%)
Hemorrhage subarachnoid (0.4%)
Deep thrombophlebitis (0.4%)
Angioedema (0.4%)
Ascites (0.4%)
Infection (0.4%)
Fibrillation ventricular (0.4%)
Anomaly vascular (0.2%)
Coagulation disorder (0.2%)
Creatinine increased (0.2%)
Hyponatremia (0.2%)
Diarrhea (0.2%)
Failure liver (0.2%)
Neoplasm of the prostate (0.2%)
Myasthenia (0.2%)
Palpitations (0.2%)
Urinary tract infection (0.2%)
Dyspepsia (0.2%)
Function kidney abnormal (0.2%)
Anemia iron deficiency (0.2%)
Alkalosis (0.2%)
Arrhythmia nodal (0.2%)
Arthralgia (0.2%)
Breast carcinoma (0.2%)
Hypokalemia (0.2%)
Ketosis (0.2%)
Cerebral infarct (0.2%)
Emotional lability (0.2%)
Edema face (0.2%)
Gastritis hemorrhagic (0.2%)
Abnormal gait (0.2%)
Hematemesis (0.2%)
Herpes zoster (0.2%)
Uremia (0.2%)
Leucopenia (0.2%)
Thrombocytopenia (0.2%)
Neurolysis (0.2%)
Ophthalmitis (0.2%)
Disorder parathyroid (0.2%)
Disorder respiratory system (0.2%)
Skin ulcer (0.2%)
Abnormal thinking (0.2%)
Vascular disorder NOS (0.2%)
Wrist drop (0.2%)
Gastritis (0.2%)
Sources:
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Disc. AE: Asthenia, Headache...
AEs leading to
discontinuation/dose reduction:
Asthenia (2.3%)
Headache (7.4%)
Dizziness (3.7%)
Pain (0.8%)
Chest pain (1.5%)
Nausea (1.5%)
Hypotension (1.4%)
Abdominal pain (0.4%)
Chills (0.4%)
Kidney failure (0.4%)
Malaise (0.4%)
Heart arrest (0.6%)
Confusion (0.4%)
Diarrhea (0.4%)
Gastroenteritis (0.2%)
Back pain (0.2%)
Acute kidney failure (0.2%)
Myasthenia (0.2%)
Nervousness (0.2%)
Pruritus (0.2%)
Heart failure (0.6%)
Dyspepsia (0.2%)
Cerebrovascular accident (0.2%)
Constipation (0.2%)
Dyspnea (0.2%)
Vomiting (0.6%)
Paresthesia (0.6%)
Function kidney abnormal (0.4%)
Palpitations (0.4%)
Syncope (0.4%)
Rash (0.6%)
Rectal hemorrhage (0.4%)
Ventricular fibrillation (0.4%)
Angioedema (0.2%)
Amblyopia (0.2%)
Anorexia (0.2%)
Neck pain (0.2%)
Carcinoma (0.2%)
Breast carcinoma (0.2%)
Dehydration (0.2%)
Edema face (0.2%)
Edema peripheral (0.2%)
Edema lung (0.2%)
Fever (0.2%)
Hyperglycemia (0.2%)
Hypertension (0.2%)
Infection (0.2%)
Fungal infection (0.2%)
Impotence (0.2%)
Ketosis (0.2%)
Breast neoplasm (0.2%)
Lab test abnormal (0.2%)
Myalgia (0.2%)
Photophobia (0.2%)
Pleural effusion (0.2%)
Somnolence (0.2%)
Sweaty (0.2%)
Vasodilation (0.2%)
Weight decrease (0.2%)
Uremia (0.2%)
Sources:
240 mg 1 times / day steady, oral
Highest studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: steady
Dose: 240 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Other AEs: Headache...
Other AEs:
Headache (57%)
Sources:
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Headache...
AEs leading to
discontinuation/dose reduction:
Headache (6 patients)
Sources:
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Headache, Nausea...
AEs leading to
discontinuation/dose reduction:
Headache (5%)
Nausea (2%)
Sources:
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Rash, Pruritus...
AEs leading to
discontinuation/dose reduction:
Rash (2%)
Pruritus (2%)
Sources:
1 ug/kg/min multiple, intravenous
Dose: 1 ug/kg/min
Route: intravenous
Route: multiple
Dose: 1 ug/kg/min
Sources:
pregnant, 26 years
Health Status: pregnant
Age Group: 26 years
Sex: F
Sources:
Disc. AE: Hypotension...
AEs leading to
discontinuation/dose reduction:
Hypotension (4 patients)
Sources:
8 ug/kg/min multiple, intravenous
Dose: 8 ug/kg/min
Route: intravenous
Route: multiple
Dose: 8 ug/kg/min
Sources:
pregnant, 26 years
Health Status: pregnant
Age Group: 26 years
Sex: F
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (severe, 1 patient)
Vomiting (severe, 1 patient)
Headache (severe, 1 patient)
Sources:
35 ug/kg/min single, intravenous
Dose: 35 ug/kg/min
Route: intravenous
Route: single
Dose: 35 ug/kg/min
Sources:
unhealthy, 50 years (range: 19 ± 74 years)
Health Status: unhealthy
Age Group: 50 years (range: 19 ± 74 years)
Sex: M+F
Sources:
Disc. AE: Hemodynamic test abnormal...
AEs leading to
discontinuation/dose reduction:
Hemodynamic test abnormal (8 patients)
Sources:
0.6 mg/h 1 times / day multiple, transdermal
Highest studied dose
Dose: 0.6 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.6 mg/h, 1 times / day
Sources:
unhealthy, 51.4 ±4.3 years
Health Status: unhealthy
Age Group: 51.4 ±4.3 years
Sex: F
Sources:
2 % 6 times / day multiple, topical
Dose: 2 %, 6 times / day
Route: topical
Route: multiple
Dose: 2 %, 6 times / day
Sources:
unhealthy, 57 - 71 years
Health Status: unhealthy
Age Group: 57 - 71 years
Sex: M
Sources:
Disc. AE: Pruritic rash, Erythema edematous...
AEs leading to
discontinuation/dose reduction:
Pruritic rash (2 patients)
Erythema edematous (2 patients)
Vesicular eruption (2 patients)
Sources:
40 mg single, oral
Overdose
unhealthy, 80 years
Other AEs: Methemoglobinemia...
0.2 mg/h 1 times / day multiple, transdermal
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Other AEs: Headache, Lightheadedness...
Other AEs:
Headache (63%)
Lightheadedness (6%)
Hypotension (4%)
Syncope (4%)
Sources:
1.5 mg 2 times / day multiple, rectal
Dose: 1.5 mg, 2 times / day
Route: rectal
Route: multiple
Dose: 1.5 mg, 2 times / day
Sources:
unhealthy, adult
Disc. AE: Hypotension...
AEs leading to
discontinuation/dose reduction:
Hypotension
Sources:
5 ug/kg 1 times / day single, subcutaneous
Dose: 5 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 5 ug/kg, 1 times / day
Sources:
unhealthy, pediatric
Health Status: unhealthy
Age Group: pediatric
Sources:
16 mg 1 times / day multiple, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Headache, Hypotension...
AEs leading to
discontinuation/dose reduction:
Headache (0.19%)
Hypotension (0.38%)
Tachycardia (0.19%)
Sources:
16 mg 1 times / day multiple, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Flushing, Headache...
AEs leading to
discontinuation/dose reduction:
Flushing (0.75%)
Headache (0.75%)
Headache (grade 3, 0.75%)
Hypotension (grade 3, 0.75%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Nausea 10%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Asthenia 14%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Tachycardia 2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Amblyopia 3%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hyperlipidemia 3%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Dizziness 32%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hyperglycemia 4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Paresthesia 4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Rhinitis 4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Sinusitis 4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Ventricular tachycardia 4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Vomiting 4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Headache 50%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Bronchitis 8%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hypotension 8%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Angioedema 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Arrhythmia 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Breast carcinoma 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Cerebrovascular accident 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Dyspnea 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Edema lung 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Gastroenteritis 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Myasthenia 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Syncope 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Uremia 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Dizziness 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Infection 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Ventricular fibrillation 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Chest pain 0.6%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Heart arrest 0.6%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Heart failure 0.6%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hypotension 0.6%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Kidney failure 0.6%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Abnormal gait 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Abnormal thinking 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Alkalosis 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Anemia iron deficiency 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Anomaly vascular 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Arrhythmia nodal 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Arthralgia 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Breast carcinoma 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Cerebral infarct 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Coagulation disorder 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Creatinine increased 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Diarrhea 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Disorder parathyroid 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Disorder respiratory system 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Dyspepsia 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Edema face 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Emotional lability 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Failure liver 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Function kidney abnormal 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Gastritis hemorrhagic 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Gastritis 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hematemesis 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Herpes zoster 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hypokalemia 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hyponatremia 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Ketosis 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Leucopenia 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Myasthenia 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Neoplasm of the prostate 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Neurolysis 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Ophthalmitis 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Palpitations 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Skin ulcer 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Thrombocytopenia 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Uremia 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Urinary tract infection 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Vascular disorder NOS 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Wrist drop 0.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Angioedema 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Ascites 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Bradycardia 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Deep thrombophlebitis 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Digitalis intoxication 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Edema lung 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Esophagitis 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Fibrillation ventricular 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Gastroenteritis 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Headache 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hemorrhage subarachnoid 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hyperkalemia 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Infection 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Osteomyelitis 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Peripheral vascular disease 0.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Accidental injury 0.6%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Asthma 0.6%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Cholecystitis 0.6%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Cholelithiasis 0.6%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Sepsis 0.6%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Supraventricular tachycardia 0.6%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Atrial fibrillation 0.8%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Gastrointestinal hemorrhage 0.8%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Gout 0.8%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Kidney failure 0.8%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Myocardial infarct 0.8%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Neoplasm 0.8%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Acute kidney failure 1%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Anemia 1%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Angina pectoris 1%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Bronchitis 1%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Cerebral ischemia 1%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Coronary artery disease 1%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Dehydration 1%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hyperglycemia 1%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hypoglycemia 1%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Infection 1%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Cellulite 1.2%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Cerebrovascular accident 1.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Dizziness 1.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Heart arrest 1.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hypotension 1.5%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Arrhythmia 1.7%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Dyspnea 1.9%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Syncope 2.1%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Pneumonia 2.3%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Ventricular tachycardia 2.7%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Heart failure 3.1%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Chest pain 6.4%
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Acute kidney failure 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Amblyopia 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Angioedema 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Anorexia 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Back pain 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Breast carcinoma 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Breast neoplasm 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Carcinoma 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Cerebrovascular accident 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Constipation 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Dehydration 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Dyspepsia 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Dyspnea 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Edema face 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Edema lung 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Edema peripheral 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Fever 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Fungal infection 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Gastroenteritis 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hyperglycemia 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hypertension 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Impotence 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Infection 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Ketosis 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Lab test abnormal 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Myalgia 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Myasthenia 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Neck pain 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Nervousness 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Photophobia 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Pleural effusion 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Pruritus 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Somnolence 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Sweaty 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Uremia 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Vasodilation 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Weight decrease 0.2%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Abdominal pain 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Chills 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Confusion 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Diarrhea 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Function kidney abnormal 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Kidney failure 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Malaise 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Palpitations 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Rectal hemorrhage 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Syncope 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Ventricular fibrillation 0.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Heart arrest 0.6%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Heart failure 0.6%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Paresthesia 0.6%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Rash 0.6%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Vomiting 0.6%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Pain 0.8%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Hypotension 1.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Chest pain 1.5%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Nausea 1.5%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Asthenia 2.3%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Dizziness 3.7%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Headache 7.4%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended|MTD
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
unhealthy, mean age 57 years
Health Status: unhealthy
Age Group: mean age 57 years
Sex: M+F
Sources:
Headache 57%
240 mg 1 times / day steady, oral
Highest studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: steady
Dose: 240 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Headache 6 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nausea 2%
Disc. AE
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Headache 5%
Disc. AE
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Pruritus 2%
Disc. AE
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Rash 2%
Disc. AE
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Hypotension 4 patients
Disc. AE
1 ug/kg/min multiple, intravenous
Dose: 1 ug/kg/min
Route: intravenous
Route: multiple
Dose: 1 ug/kg/min
Sources:
pregnant, 26 years
Health Status: pregnant
Age Group: 26 years
Sex: F
Sources:
Headache severe, 1 patient
Disc. AE
8 ug/kg/min multiple, intravenous
Dose: 8 ug/kg/min
Route: intravenous
Route: multiple
Dose: 8 ug/kg/min
Sources:
pregnant, 26 years
Health Status: pregnant
Age Group: 26 years
Sex: F
Sources:
Nausea severe, 1 patient
Disc. AE
8 ug/kg/min multiple, intravenous
Dose: 8 ug/kg/min
Route: intravenous
Route: multiple
Dose: 8 ug/kg/min
Sources:
pregnant, 26 years
Health Status: pregnant
Age Group: 26 years
Sex: F
Sources:
Vomiting severe, 1 patient
Disc. AE
8 ug/kg/min multiple, intravenous
Dose: 8 ug/kg/min
Route: intravenous
Route: multiple
Dose: 8 ug/kg/min
Sources:
pregnant, 26 years
Health Status: pregnant
Age Group: 26 years
Sex: F
Sources:
Hemodynamic test abnormal 8 patients
Disc. AE
35 ug/kg/min single, intravenous
Dose: 35 ug/kg/min
Route: intravenous
Route: single
Dose: 35 ug/kg/min
Sources:
unhealthy, 50 years (range: 19 ± 74 years)
Health Status: unhealthy
Age Group: 50 years (range: 19 ± 74 years)
Sex: M+F
Sources:
Erythema edematous 2 patients
Disc. AE
2 % 6 times / day multiple, topical
Dose: 2 %, 6 times / day
Route: topical
Route: multiple
Dose: 2 %, 6 times / day
Sources:
unhealthy, 57 - 71 years
Health Status: unhealthy
Age Group: 57 - 71 years
Sex: M
Sources:
Pruritic rash 2 patients
Disc. AE
2 % 6 times / day multiple, topical
Dose: 2 %, 6 times / day
Route: topical
Route: multiple
Dose: 2 %, 6 times / day
Sources:
unhealthy, 57 - 71 years
Health Status: unhealthy
Age Group: 57 - 71 years
Sex: M
Sources:
Vesicular eruption 2 patients
Disc. AE
2 % 6 times / day multiple, topical
Dose: 2 %, 6 times / day
Route: topical
Route: multiple
Dose: 2 %, 6 times / day
Sources:
unhealthy, 57 - 71 years
Health Status: unhealthy
Age Group: 57 - 71 years
Sex: M
Sources:
Methemoglobinemia grade 5, 1 patient
40 mg single, oral
Overdose
unhealthy, 80 years
Hypotension 4%
0.2 mg/h 1 times / day multiple, transdermal
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Syncope 4%
0.2 mg/h 1 times / day multiple, transdermal
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Lightheadedness 6%
0.2 mg/h 1 times / day multiple, transdermal
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Headache 63%
0.2 mg/h 1 times / day multiple, transdermal
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Hypotension Disc. AE
1.5 mg 2 times / day multiple, rectal
Dose: 1.5 mg, 2 times / day
Route: rectal
Route: multiple
Dose: 1.5 mg, 2 times / day
Sources:
unhealthy, adult
Headache 0.19%
Disc. AE
16 mg 1 times / day multiple, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Tachycardia 0.19%
Disc. AE
16 mg 1 times / day multiple, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Hypotension 0.38%
Disc. AE
16 mg 1 times / day multiple, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Flushing 0.75%
Disc. AE
16 mg 1 times / day multiple, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Headache 0.75%
Disc. AE
16 mg 1 times / day multiple, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Headache grade 3, 0.75%
Disc. AE
16 mg 1 times / day multiple, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Hypotension grade 3, 0.75%
Disc. AE
16 mg 1 times / day multiple, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effect of alterations of arterial blood pressure and heart rate on segmental dyskinesis during acute myocardial ischemia and following coronary reperfusion.
1975 Jan
Venodilator effects of adenosine triphosphate and sodium nitroprusside; comparisons during controlled hypotension.
1987 Sep 1
[Nitric oxide dependence of the anti-thrombotic effect of sydnonimines in coronary arteries of swine].
1991
Comparative cardiovascular effects of SNP, ATP and phentolamine during norepinephrine-induced hypertension in dogs.
1991 Oct
CAS 936, a novel syndnonimine with direct vasodilating and nitric oxide-donating properties: effects on isolated blood vessels.
1991 Oct
Baroreflex changes produced by serotonergic or catecholaminergic lesions in the rat nucleus tractus solitarius.
1992 Apr
Cardiovascular effects of the new nitric oxide donor, pirsidomine. Hemodynamic profile and tolerance studies in anesthetized and conscious dogs.
1992 Sep 10
Effects of an orally active NO-releasing agent, CAS 936, and its active metabolite, 3754, on cardiac and coronary dynamics in normal conscious dogs and after pacing-induced heart failure.
1993
Effects of nitric oxide-containing compounds on increases in cytosolic ionized Ca2+ and on aggregation of human platelets.
1993 Jan 4
Nitric oxide controls cardiac substrate utilization in the conscious dog.
1999 Nov
In vivo evidence that isoproterenol may increase heart rate in the rat by mechanisms in addition to activation of cardiac beta(1)- or beta(2)-adrenoceptors.
1999 Oct 15
[Reactivity of cerebral vessels in patients with circulatory encephalopathy, arterial hypertension and cerebral hypoperfusion risk].
2001
Glyceryl trinitrate and acute uterine relaxation: a literature review.
2001 Apr
Nonadrenergic, noncholinergic relaxation of human isolated corpus cavernosum induced by scorpion venom.
2001 Apr
Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis.
2001 Apr
NO-dependent vasorelaxation is impaired after gene transfer of inducible NO-synthase.
2001 Aug
Improved analysis of brachial artery ultrasound using a novel edge-detection software system.
2001 Aug
Effects of molsidomine on scopolamine-induced amnesia and hypermotility in the rat.
2001 Aug 31
[Aspirin and nitroglycerine: a good combination for gastric mucosa].
2001 Aug-Sep
Investigations into migraine pathogenesis: time course for effects of m-CPP, BW723C86 or glyceryl trinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleus caudalis (TNC).
2001 Feb
Acute myocardial infarction secondary to coronary vasospasm during withdrawal from industrial nitroglycerin exposure--a case report.
2001 Feb
Reduced venous responsiveness to endothelin-1 but not noradrenaline in hypertensive chronic renal failure.
2001 Feb
NO donors inhibit Leishmania infantum cysteine proteinase activity.
2001 Feb 9
Impaired vasodilator response to organic nitrates in isolated basilar arteries.
2001 Jan
Sodium nitroprusside compared with isoflurane-induced hypotension: the effects on brain oxygenation and arteriovenous shunting.
2001 Jul
Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus.
2001 Jul
Different mechanisms of isoproterenol-induced and nitroglycerin-induced syncope during head-up tilt in patients with unexplained syncope: important role of epinephrine in nitroglycerin-induced syncope.
2001 Jul
Gender difference in age-related changes in vascular function.
2001 Jul
Transoesophageal acoustic quantification for evaluation of cardiac function during laparoscopic surgery.
2001 Jul
Pseudonormal diastolic filling unmasked with glyceryl trinitrate in patients with type 2 diabetes with poor metabolic control.
2001 Jul
Long-term outcome of patients with ergonovine induced coronary constriction not associated with ischemic electrocardiographic changes.
2001 Jun
Changes in endothelium-dependent vasodilatation and alpha-adrenergic responses in resistance vessels during the menstrual cycle in healthy women.
2001 Jun
Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension.
2001 Mar
Urban-rural differences in the quality of care for medicare patients with acute myocardial infarction.
2001 Mar 12
Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure.
2001 May
An update on nesiritide for treatment of decompensated heart failure.
2001 May
Glyceryl trinitrate ointment as a potential treatment for primary vaginismus.
2001 May
Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model.
2001 May 1
[Nitrate headache in blasting work].
2001 May 15
Treatment of chronic anal fissure with topical glyceryl trinitrate: a double-blind, placebo-controlled trial.
2001 May-Jun
Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27-/- mice but not in cerebrotendinous xanthomatosis.
2001 Sep 14
Acute sympathoexcitatory action of angiotensin II in conscious baroreceptor-denervated rats.
2002 Aug
Myocardial tissue oxygen during coronary artery constriction and hypotension in dogs.
2002 Jul
Internal thoracic artery flow competition: studies in a canine H-graft model.
2003 Jan
Ferulic acid inhibits endothelial cell proliferation through NO down-regulating ERK1/2 pathway.
2004 Dec 15
The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway.
2004 Nov 5
Regulation of cytoplasmic stress granules by apoptosis-inducing factor.
2004 Sep 1
Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition.
2005 Jan
Effect of nitric oxide on mitochondrial respiratory activity of human articular chondrocytes.
2005 Mar
NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1.
2006 Aug 17
Patents

Sample Use Guides

mice were treated three times a week for 3 weeks with intravenous tail vein injections of either vehicle (2.25% Pluronic P123 in PBS) or JS-K (6 μmol/kg in the vehicle).
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment: In epithelial cells, NO increased apoptosis by 2.1 +/- 0.2-fold, augmented mRNA expression of Bax, and reduced expression of Bcl-2 compared with basal cultures. In stromal cells, NO increased cell proliferation in a dose-dependent manner, an effect that was blocked by a NO synthase inhibitor.
Human U87 cells (HTB-14), fibroblasts (CRL-1634), and astrocytes (CRL-8621; ATCC) were cultured in Dulbecco’s Minimal Essential Eagle Medium (DMEM; Gibco, USA) supplemented with 10% fetal calf serum (FCS) and penicillin (100U/mL)/streptomycin (100mg/mL) under normoxic conditions (95% air, 5% CO2, and 37°C). The nitric oxide donor JS-K (O2-(2.4-dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-yl] diazen-1-ium1,2-diolate, CAS 7054 32-12-8) was dissolved in 100% dimethyl sulfoxide (DMSO) in a concentration of 5.2mM. U87 was incubated with JS-K doses of 0–15µM for 4 h. The JS-K solvent control (DMSO≤1%) was adjusted to the highest JS-K concentration used in these experiments. A cesium source emitting γ-radiation was used for radiotherapy (RT; 3×2Gy) with a 24-h interval between each RT dose (Isotopen Diagnostik CIS, Germany).
Name Type Language
DILUTED ISOSORBIDE MONONITRATE
USP-RS  
Preferred Name English
ISOSORBIDE MONONITRATE
INN   JAN   MART.   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
INN   USAN  
Official Name English
IS-5MN
Code English
ISOSORBIDE 5-MONONITRATE
Common Name English
ISOSORBIDE MONONITRATE [USP IMPURITY]
Common Name English
BM 22.145
Code English
IS 5-MN
Code English
ISOSORBIDE MONONITRATE [MART.]
Common Name English
Isosorbide mononitrate [WHO-DD]
Common Name English
ISOSORBIDE DINITRATE ISOSORBIDE-5-MONONITRATE [MI]
Common Name English
ISOSORBIDE-5-MONONITRATE
Common Name English
MONOCORD
Brand Name English
MONOKET
Brand Name English
ISOSORBIDE MONONITRATE [JAN]
Common Name English
DILUTED ISOSORBIDE MONONITRATE [USP-RS]
Common Name English
BM 22.145IS 5-MNAHR-4698
Code English
ISMO
Brand Name English
ISOSORBIDE MONONITRATE [USAN]
Common Name English
ISOSORBIDE MONONITRATE [ORANGE BOOK]
Common Name English
ISOSORBIDE 5-NITRATE
Common Name English
IS-5-MN
Code English
BM-22.145
Code English
ISOSORBIDE MONONITRATE [VANDF]
Common Name English
BM-22-145
Code English
ISO-5-MONONITRATE
Common Name English
BM-22145
Code English
AHR-4698
Code English
ISMN
Common Name English
D-GLUCITOL, 1,4:3,6-DIANHYDRO-, 5-NITRATE
Systematic Name English
DILUTED ISOSORBIDE MONONITRATE [USP MONOGRAPH]
Common Name English
CORANGIN
Brand Name English
NSC-758619
Code English
ISOSORBIDE DINITRATE, DILUTED IMPURITY C [EP IMPURITY]
Common Name English
isosorbide mononitrate [INN]
Common Name English
IMDUR
Brand Name English
Classification Tree Code System Code
NDF-RT N0000009909
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
NDF-RT N0000007647
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
WHO-ATC C01DA14
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
NCI_THESAURUS C29707
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
NDF-RT N0000007647
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
NDF-RT N0000175415
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
NDF-RT N0000007647
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
NDF-RT N0000007647
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
WHO-VATC QC01DA14
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
Code System Code Type Description
ECHA (EC/EINECS)
240-197-2
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
USAN
Z-57
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
CHEBI
6062
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
RS_ITEM_NUM
1353102
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
RXCUI
28004
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY RxNorm
NSC
758619
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
SMS_ID
100000090392
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
INN
5177
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
DAILYMED
LX1OH63030
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
MERCK INDEX
m6541
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY Merck Index
EVMPD
SUB08336MIG
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
FDA UNII
LX1OH63030
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
MESH
C030397
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
EVMPD
SUB30087
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
PUBCHEM
27661
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
NCI_THESAURUS
C47575
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
DRUG BANK
DB01020
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
DRUG CENTRAL
1506
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
WIKIPEDIA
ISOSORBIDE MONONITRATE
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
EPA CompTox
DTXSID9023176
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
CAS
16051-77-7
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
EVMPD
SUB12087MIG
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
ALTERNATIVE
ChEMBL
CHEMBL1311
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY
IUPHAR
7052
Created by admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
PRIMARY